IMULIFE Launches AI Initiative to Track Immune Biomarkers Over Time
News related to:IMULIFE · 2 min read
NEW YORK, October 6, 2026 /CourierPR/ -- IMULIFE, a U.S. health company founded by Gene Gui, has launched a new initiative aimed at tracking immune biomarkers over time using artificial intelligence. The company’s IT-X framework is designed to compare blood-based immune data across repeated measurements, analyzing nearly 200 immune-related biomarkers and analytical parameters.
According to Gui, the initiative seeks to establish individual baselines and compare them with subsequent measurements. By following data across multiple time points, IMULIFE hopes to develop a comprehensive record of how immune-related indicators change over time. The company’s areas of interest include immune aging, inflammatory activity, and other patterns of immune response.
Gui explained that the longer-term objective is to build a continuously updated personal immune health record. This record would be used to explore the relationships among diet, sleep, stress, lifestyle, and immune biomarkers. These relationships would be examined as correlations, without assuming that one factor caused a particular biological change.
The company is also exploring short-chain fatty acids, metabolites produced by gut bacteria, as a potential additional source of data. IMULIFE plans to study whether changes in gut microbial metabolism correlate with immune-related measurements, including markers associated with inflammation and immune aging.
The IT-X framework, co-developed by Gui, his research team, and artificial intelligence specialists, is designed to apply immunology research and data interpretation expertise more consistently across repeated analyses. The company plans to continue developing its framework as part of this effort to organize and interpret longitudinal data.
In addition to the IT-X framework, IMULIFE is also investigating short-chain fatty acids, which are metabolites produced by gut bacteria. The company aims to determine if changes in gut microbial metabolism correlate with immune-related measurements, such as markers associated with inflammation and immune aging.
While the initiative outlines development goals and planned areas of investigation, drawing meaningful conclusions from the data will depend on the quality of the measurements and validation of the biomarkers and analytical models. The company has not yet presented clinical validation results or demonstrated that changes in the measured indicators produce health benefits.
Gene Gui, the founder of IMULIFE, emphasized the importance of the initiative.
The company's work in immune data analysis and tracking biological measurements over time is part of its broader mission to improve public health through advanced biotechnology. IMULIFE continues to develop innovative solutions to address the challenges of immune health and aging.